Skip to main content
Journal cover image

Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections.

Publication ,  Journal Article
Rim, J; Gallini, J; Jasien, C; Cui, X; Phillips, L; Trammell, A; Sadikot, RT
Published in: The American journal of the medical sciences
July 2022

Sepsis is one of the leading causes of hospital mortality, and diabetes is a risk factor for the development of infections. Although strong evidence has shown an association between metformin and reduced risk of infections, the risk of developing infections with newer classes of oral anti-diabetic drugs (OADs) has been less certain. Our study aims to examine the association between outpatient OAD use and hospital admissions for infections.The study cohort included 1.39 million adults with diabetes utilizing the Veterans Health Affairs Corporate Data Warehouse. Multivariate logistic regression was used to estimate the effect of each drug class on hospital admission for infection while adjusting for covariates.After adjusting for covariates, those who took metformin during the study period had 3.3% lower odds of hospital admission for infection compared to those who were never on metformin (OR 0.97, 95% CI 0.95-0.98). OADs that were associated with a statistically significant increased odds of being admitted included meglitinides (OR 1.22, 95% CI 1.07-1.38), SGLT2 inhibitors (OR 1.16, 95% CI 1.08-1.24), alpha-glucosidase inhibitors (OR 1.09, 95% CI 1.04-1.15), and DPP4 inhibitors (OR 1.04, 95% CI 1.01-1.06).Metformin was associated with lower odds of hospital admission for infection while meglitinides, SGLT2 inhibitors, alpha-glucosidase inhibitors, and DPP4 inhibitors were associated with higher odds of admission for infection.

Duke Scholars

Published In

The American journal of the medical sciences

DOI

EISSN

1538-2990

ISSN

0002-9629

Publication Date

July 2022

Volume

364

Issue

1

Start / End Page

53 / 58

Related Subject Headings

  • Sodium-Glucose Transporter 2 Inhibitors
  • Metformin
  • Intensive Care Units
  • Hypoglycemic Agents
  • Humans
  • Hospitals
  • General & Internal Medicine
  • Dipeptidyl-Peptidase IV Inhibitors
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rim, J., Gallini, J., Jasien, C., Cui, X., Phillips, L., Trammell, A., & Sadikot, R. T. (2022). Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections. The American Journal of the Medical Sciences, 364(1), 53–58. https://doi.org/10.1016/j.amjms.2022.01.003
Rim, Jeeyon, Julia Gallini, Christine Jasien, Xiangqin Cui, Lawrence Phillips, Aaron Trammell, and Ruxana T. Sadikot. “Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections.The American Journal of the Medical Sciences 364, no. 1 (July 2022): 53–58. https://doi.org/10.1016/j.amjms.2022.01.003.
Rim J, Gallini J, Jasien C, Cui X, Phillips L, Trammell A, et al. Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections. The American journal of the medical sciences. 2022 Jul;364(1):53–8.
Rim, Jeeyon, et al. “Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections.The American Journal of the Medical Sciences, vol. 364, no. 1, July 2022, pp. 53–58. Epmc, doi:10.1016/j.amjms.2022.01.003.
Rim J, Gallini J, Jasien C, Cui X, Phillips L, Trammell A, Sadikot RT. Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections. The American journal of the medical sciences. 2022 Jul;364(1):53–58.
Journal cover image

Published In

The American journal of the medical sciences

DOI

EISSN

1538-2990

ISSN

0002-9629

Publication Date

July 2022

Volume

364

Issue

1

Start / End Page

53 / 58

Related Subject Headings

  • Sodium-Glucose Transporter 2 Inhibitors
  • Metformin
  • Intensive Care Units
  • Hypoglycemic Agents
  • Humans
  • Hospitals
  • General & Internal Medicine
  • Dipeptidyl-Peptidase IV Inhibitors
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus